Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of nivolumab in uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma
jRCT2080223157Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in Cervical Cancer (CC), endometrial cancer (EC) and soft tissue sarcoma (STS) (3 cohorts), sponsored by Ono Pharmaceutical. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2080223157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223157.